Eton Pharmaceuticals (ETON) Revenue (2019 - 2026)

Eton Pharmaceuticals has disclosed Revenue across 8 years of filings, most recently posting $37.6 million for Q2 2026.

• In Q2 2026, Revenue rose 98.59% year-over-year to $37.6 million; the TTM figure through Jun 2026 stood at $100.3 million (up 72.32% YoY), while the FY2025 annual figure was $80.0 million, up 104.94% from the prior year.
• Revenue came in at $37.6 million for Q2 2026 at Eton Pharmaceuticals, up from $21.3 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $37.6 million in Q2 2026 to a low of $2.2 million in Q1 2022.
• Average Revenue over 5 years is $12.2 million, with a median of $9.1 million recorded in 2024.
• The largest YoY upside for Revenue was 315.35% in 2022 against a maximum downside of 81.71% in 2022.
• Over 5 years, Revenue stood at $8.5 million in 2022, then retreated by 13.94% to $7.3 million in 2023, then soared by 59.26% to $11.6 million in 2024, then surged by 82.72% to $21.3 million in 2025, then jumped by 76.63% to $37.6 million in 2026.
• Per Business Quant data, the three most recent Revenue figures were $37.6 million in Q2 2026, $21.3 million in Q4 2025, and $22.5 million in Q3 2025.